Intravenous Immunoglobulin (IVIG) Market Demand, Growth, Trend, Business Opportunities, Manufacturers and Research 2030

The global intravenous immunoglobulin (IVIG) market size is expected to reach USD 20.22 billion in 2030

NEW YORK, NEW YORK, UNITED STATES, June 22, 2022 / — Rising incidence of immunodeficiency diseases and increase in geriatric population are key factors behind the revenue growth of the market

According to the latest report by Reports and Data, the global intravenous immunoglobulin (IVIG) market size is projected to reach US$20.22 billion in 2030, registering a CAGR of 6.9% in sales during the forecast period. Rising incidence of immunodeficiency diseases and steady increase in geriatric population are key factors expected to drive the revenue growth of the market during the forecast period.

With the increase in cases of primary and acquired immunodeficiency diseases and disorders such as hypogammaglobulinemia, immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome, Kawasaki disease, the healthcare ecosystem is being impacted by the increasing demand for a more diversified resource allocation to meet the demands of the to meet changing dynamics in healthcare. Healthcare infrastructure faces a greater burden from the ever-increasing number of immunoglobulin-deficient patients. With the increasing awareness and adoption of IVIG therapies, the demand for adequate treatment is increasing, creating strong demand for the plasma market. Therefore, given the changing dynamics in healthcare, the need for proper resource allocation for healthcare management is of great importance. Proper allocation of resources boosts the entire supply chain and contributes to the growth of the IVIG market.

Major companies profiled in the report include

Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd, Shanghai RAAS Blood Products Co., Ltd, CSL Behring LLC, ADMA Biologics, Inc., Baxalta Inc., Biotest AG, Kedrion Biopharma, Inc., China Biologic Products Holdings, Inc., Octapharma AG, Grifols SA, Pfizer Inc. and LFB Biomedicaments SA.

Get a sample of the report at

The report is an investigative study that determines the market growth and scope based on market trends, changes in consumer behavior, consumption and production patterns, the portfolio of products offered by the market, growth rate, drivers and restraints, financial standing, existing challenges and market restraints for intravenous immunoglobulin (IVIG).

The report discusses in detail the global production capacity, demand and supply ratio, market dynamics and a comprehensive analysis of the competitive landscape. It provides an industry-wide analysis of each player’s market share along with their business portfolio, production and manufacturing capacity, product portfolio, expansion plans, financial position, and strategic alliances such as mergers and acquisitions, joint ventures, and collaborations. among other.

Order this report at

The regional breakdown of the market analyzes major market segments such as North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. The report thoroughly discusses the market growth, market size, sales growth, market share, production and consumption, demand and supply, current and emerging trends, and technological developments in each region.

The key geographic regions analyzed in the market report are:

North America (USA, Canada)
Europe (UK, Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East and Africa (Saudi Arabia, UAE, South Africa, Rest of MEA)
Intravenous Immunoglobulin (IVIG) Market Segment By Type:

Product Type Outlook (Revenue, $Bn; (2019-2030)

Immunoglobulin G (IgG)
Immunoglobulin A (IgA)
Immunoglobulin M (IgM)
Immunoglobulin E (IgE)
Immunoglobulin D (IgD)
Bid Outlook (Revenue, $Bn; 2019-2030)

immunodeficiency diseases
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Congenital AIDS
Myasthenia gravis
Multifocal motor neuropathy
Guillain Barre Syndrome
Kawasaki diseases
Form Outlook (Revenue, $Bn; 2019-2030)

End Use Outlook (Revenue, $Bn; 2019-2030)

home care
Some key highlights in the report

The Hypogammaglobulinemia segment is expected to lead the global market in terms of revenue contribution. Hypogammaglobulinemia is the most common primary immunodeficiency disorder and affects a majority of immunocompromised patients caused by low antibody levels. The standard of care for hypogammaglobulinemia is IgG replacement to minimize potentially fatal infections and reduce complications, thereby improving patient survival and quality of life.
The liquid segment is expected to account for a larger market share during the forecast period. The liquid form is more convenient for patients due to the relatively shorter infusion time. In addition, the ease of preparation and administration makes it the most acceptable for healthcare workers and patients, boosting growth for this segment.
North America will account for the largest share of the IVIG market during the forecast period due to the increasing number of patients with immunological diseases and the rising geriatric population
Request report customization @

Thank you for reading our report. Any other questions or questions about customization, please contact us to learn more. Our team will clear your doubts and make sure the report is customized to your needs.

About reports and data

Reports and Data is a market research and consulting company offering syndicated research reports, custom research reports and consulting services. Our solutions are solely focused on your purpose of locating, targeting and analyzing changes in consumer behavior across demographics and industries, and helping customers make smarter business decisions. We offer market research studies that ensure relevant and fact-based research across a wide range of industries including healthcare, technology, chemical, energy and energy. We are constantly updating our research offerings to ensure our clients are up to date with the latest trends in the market. Reports and Data has a strong base of experienced analysts from different disciplines.

Tushar Rajput
reports and data
+ +12127101370
email us here
Visit us on social media:

Leave a Comment